Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.43 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | HLCS | P50747 | 2/20 | 0.42 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.36 |
| ▸ | GBA1 | P04062 | 3/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.35 |
| ▸ | SPHK1 | Q9NYA1 | 2/20 | 0.34 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2734736 | 1.00 | ALDH1A1 (0.46) | ALDH1A1S1PR3EPHX1TSHRTHRB | |
| SCHEMBL8532189 | 1.00 | ALDH1A1 (0.46) | ALDH1A1S1PR3EPHX1TSHRTHRB | |
| SCHEMBL8537115 | 1.00 | ALDH1A1 (0.46) | ALDH1A1S1PR3EPHX1TSHRTHRB | |
| SCHEMBL2326236 | 1.00 | ALDH1A1 (0.46) | ALDH1A1S1PR3EPHX1TSHRTHRB | |
| SCHEMBL11388793 | 1.00 | ALDH1A1 (0.46) | ALDH1A1S1PR3EPHX1TSHRTHRB | |
| Phosphine SCHEMBL28301587 | 0.97 | ALDH1A1 (0.44) | ALDH1A1S1PR3EPHX1TSHRTHRB | |
| SCHEMBL2108191 | 0.97 | — | — | |
| SCHEMBL182402 | 0.89 | — | — | |
| SCHEMBL8121418 | 0.86 | CYP1A2 (0.39) | ALDH1A1S1PR3EPHX1TSHRTHRB | |
| SCHEMBL2580848 | 0.84 | ALDH1A1 (0.39) | ALDH1A1S1PR3EPHX1TSHRTHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4524216-B1 | INK COMPOSITION, PRODUCTION METHOD THEREOF, COMPOSITE PREPARED THEREFROM, AND ELECTRONIC DEVICE INCLUDING THE SAME | SAMSUNG ELECTRONICS CO LTD (KR) | 2026-04-22 | — | — | EP | disclosed |
| US-20260090229-A1 | SEMICONDUCTOR NANOPARTICLE, METHOD OF PRODUCING THE SAME AND ELECTRONIC DEVICE INCLUDING THE SAME | SAMSUNG ELECTRONICS CO LTD (KR) | 2026-03-26 | — | — | US | disclosed |
| US-20260052831-A1 | SEMICONDUCTOR NANOPARTICLE, METHOD OF PRODUCING THE SAME AND ELECTRONIC DEVICE INCLUDING THE SAME | SAMSUNG ELECTRONICS CO LTD (KR) | 2026-02-19 | — | — | US | disclosed |
| EP-4696761-A1 | SEMICONDUCTOR NANOPARTICLE, METHOD OF PRODUCING THE SAME AND ELECTRONIC DEVICE INCLUDING THE SAME | Samsung Electronics Co., Ltd. (KR) | 2026-02-18 | — | — | EP | disclosed |
| EP-4372066-B1 | INK COMPOSITION, PRODUCTION METHOD THEREOF, COMPOSITE PREPARED THEREFROM, AND ELECTRONIC DEVICE INCLUDING THE SAME | SAMSUNG ELECTRONICS CO LTD (KR) | 2025-10-29 | — | — | EP | disclosed |
| US-20250257263-A1 | SEMICONDUCTOR NANOPARTICLE, PRODCUTION METHOD THEREOF, ELECTRONIC DEVICE INCLUDING THE SAME | SAMSUNG DISPLAY CO., LTD. (KR) | 2025-08-14 | — | — | US | disclosed |
| EP-4596655-A1 | SEMICONDUCTOR NANOPARTICLE, METHOD OF PRODUCING THE SAME AND ELECTRONIC DEVICE INCLUDING THE SAME | Samsung Electronics Co., Ltd. (KR) | 2025-08-06 | — | — | EP | disclosed |
| US-20250248196-A1 | SEMICONDUCTOR NANOPARTICLE, METHOD OF PRODUCING THE SAME AND ELECTRONIC DEVICE INCLUDING THE SAME | SAMSUNG DISPLAY CO., LTD. (KR) | 2025-07-31 | — | — | US | disclosed |
| US-20250243376-A1 | INK COMPOSITION, PRODUCTION METHOD THEREOF, COMPOSITE PREPARED THEREFROM, AND ELECTRONIC DEVICE INCLUDING THE SAME | SAMSUNG DISPLAY CO., LTD. (KR) | 2025-07-31 | — | — | US | disclosed |
| EP-4592374-A2 | INK COMPOSITION, PRODUCTION METHOD THEREOF, COMPOSITE PREPARED THEREFROM, AND ELECTRONIC DEVICE INCLUDING THE SAME | Samsung Electronics Co., Ltd. (KR) | 2025-07-30 | — | — | EP | disclosed |
| EP-2721652-A1 | QUANTUM DOT CONTAINING LIGHT MODULE | Miller, Gregory (US) | 2014-04-23 | — | — | EP | disclosed |
| EP-2721633-A1 | STABILIZED NANOCRYSTALS | Qu, Lianhua (US) | 2014-04-23 | — | — | EP | disclosed |
| WO-2012177761-A1 | STABILIZED NANOCRYSTALS | CRYSTALPLEX CORPORATION (US) | 2012-12-27 | — | — | WO | disclosed |
| WO-2012177793-A1 | QUANTUM DOT CONTAINING LIGHT MODULE | CRYSTALPLEX CORPORATION (US) | 2012-12-27 | — | — | WO | disclosed |
| US-20110256404-A1 | NANOCRYSTALS WITH FUNCTIONAL LIGANDS | Life Technologies Corporation | 2011-10-20 | — | — | US | disclosed |
| EP-2344417-A2 | NANOCRYSTALS WITH FUNCTIONAL LIGANDS | Life Technologies Corporation (US) | 2011-07-20 | — | — | EP | disclosed |
| WO-2010039897-A2 | NANOCRYSTALS WITH FUNCTIONAL LIGANDS | Life Technologies Corporation (US) | 2010-04-08 | — | — | WO | disclosed |
| US-6696595-B2 | ESTERIFYING AN ADAMANTANE COMPOUND HAVING AN -OH GROUP, -OM GROUP OR OR DIVALENT ALIPHATIC HYDROCARBON GROUP, AND DISTILLING THE ESTER PRODUCT IN PRESENCE OF AN INERT HETEROCYCLIC COMPOUND WHICH IS STABLE UNDER DISTILLATION | TOKUYAMA CORPORATION (JP) | 2004-02-24 | — | — | US | disclosed |
| US-20030120107-A1 | Process of the preparation of high-purity alkyladamantyl esters | TOKUYAMA CORPORATION (JP) | 2003-06-26 | — | — | US | disclosed |
| EP-1284256-A1 | PROCESS OF THE PREPARATION OF HIGH-PURITY ALKYLADAMANTYL ESTERS | TOKUYAMA CORPORATION (JP) | 2003-02-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260090229-A1 | SEMICONDUCTOR NANOPARTICLE, METHOD OF PRODUCING THE SAME AND ELECTRONIC DEVICE INCLUDING THE SAME | AGO2, EXOSC10, CD63 | ALDH1A1 761/4885S1PR3 4568/4885EPHX1 3131/4885 |
| US-20260052831-A1 | SEMICONDUCTOR NANOPARTICLE, METHOD OF PRODUCING THE SAME AND ELECTRONIC DEVICE INCLUDING THE SAME | IQGAP1, MKI67, CD47 | ALDH1A1 1476/4885S1PR3 3960/4885EPHX1 3668/4885 |
| US-20030120107-A1 | Process of the preparation of high-purity alkyladamantyl esters | TET2, MSMO1, ACMSD | ALDH1A1 591/4885S1PR3 3383/4885EPHX1 517/4885 |
| US-20110256404-A1 | NANOCRYSTALS WITH FUNCTIONAL LIGANDS | EPCAM, L1CAM, SELPLG | ALDH1A1 1749/4885S1PR3 2020/4885EPHX1 4207/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.